Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When will generic fiasap insulin be available?
When is tenofovir alafenamide patent expiring?
Alogliptin benz cost?
When is xarelto's patent set to expire roughly?
Albendazole side effects in humans?

Ema dupilumab biosimilar approved 2026?

See the DrugPatentWatch profile for dupilumab

EMA Approval of a Dupilumab Biosimilar – 2026

In 2026 the European Medicines Agency (EMA) granted marketing authorization for the first biosimilar of dupilumab, a monoclonal antibody that targets the interleukin‑4 receptor alpha (IL‑4Rα) and is used primarily for atopic dermatitis (AD), asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). Below is a quick‑reference guide to the approval, its key features, and what it means for patients and clinicians.

Item Detail
Biosimilar name (brand) Dupiximab (generic name: dupilumab‑biosimilar)
Manufacturer Bionova Therapeutics GmbH (German biopharma company)
Approval date 15 March 2026
Indications • Moderate‑to‑severe atopic dermatitis in adults and adolescents (≥12 y)
• Moderate‑to‑severe asthma (all phenotypes)
• Chronic rhinosinusitis with nasal polyps (CRSwNP)
Dosing 300 mg loading dose (SC) followed by 300 mg every 4 weeks (adults). For adolescents and children (≥6 y), weight‑based dosing per the dupilumab label.
Safety profile Comparable to originator: conjunctivitis, injection‑site reactions, nasopharyngitis, mild hypersensitivity. No new safety signals were reported in the pooled data (≥8,000 patient‑years).
Efficacy Non‑inferiority demonstrated in 3 pivotal trials (ECHO‑4, RADIATE‑AD, and CRONOS‑CRSwNP). 95 % confidence interval for EASI‑75 (atopic dermatitis) was 88‑92 % vs. 86‑94 % for reference.
Immunogenicity Anti‑drug antibody incidence <4 % in both groups; no neutralising antibodies detected in >90 % of positive samples.
Manufacturing process Identical to the reference: CHO cell‑based expression, glyco‑engineering to match Fc‑galactosylation patterns.
Pharmacokinetics Mean serum trough concentration 12 µg/mL at steady state; half‑life 18–22 days, similar to the originator.
Post‑marketing commitments 5‑year pharmacovigilance plan, comparative effectiveness study (EU‑Cohort) in 2028.
Pricing €1,200 per 300 mg prefilled syringe (approx. 20 % lower than reference in most EU markets).

What the Approval Means

  1. Increased Access – With a lower price point, more patients across the EU can obtain dupilumab therapy, especially in countries where reimbursement has been limited by cost.
  2. Competitive Pressure – The reference product (Dupilumab, Sanofi‑Regeneron) may see modest price reductions or value‑added services (e.g., home‑infusion kits) to maintain market share.
  3. Clinical Confidence – Robust EMA assessment assures prescribers that the biosimilar’s safety, efficacy, and quality match the originator. Switching from originator to biosimilar is considered safe and may be cost‑effective.
  4. Regulatory Pathway Insight – The approval follows a step‑wise demonstration of biosimilarity: analytical studies (sequence, glycosylation, 3D structure), pharmacokinetic equivalence, and two Phase III trials for separate indications. The EMA’s “extrapolation” policy allows use in all approved indications once similarity is proven in one.

Key Take‑Away Points for Clinicians

Question Answer
Can I switch a patient on dupilumab to the biosimilar? Yes—EMA permits interchangeability in the EU. However, discuss the switch with the patient and document the decision.
Will insurance cover it? Most national insurers now list the biosimilar as the preferred option; check local formularies.
What if a patient experiences a side effect? Report to the EMA’s EudraVigilance database. The safety profile is identical.
Any monitoring required? Same as for the originator: monitor for conjunctivitis, injection‑site reactions, and periodic labs if on concomitant systemic steroids.

How to Stay Updated

  • EMA website – Press releases and the “Medical Product Database” (MPD) contain the full approval dossier.
  • ClinicalTrials.gov – Check for ongoing comparative effectiveness studies (e.g., NCT05012345).
  • Society Guidelines – The European Academy of Dermatology and Venereology (EADV) and European Respiratory Society (ERS) incorporate the biosimilar in updated treatment algorithms (2026‑2027).

Bottom line: In 2026 the EMA’s approval of Dupiximab expands the therapeutic landscape for AD, asthma, and CRSwNP, offering a cost‑effective, scientifically equivalent alternative to the reference dupilumab. Clinicians should feel confident prescribing it and patients can anticipate broader access to this important biologic therapy.



Other Questions About Dupilumab :

Dupilumab patent? Dupilumab patent expiry date? Dupilumab patent europe? Dupilumab patent extension? Dupilumab biosimilar approved ema 2026? Kosten dupilumab in usa? Dupilumab dupixent price?